In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized (64)Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study

Peritoneal dissemination of pancreatic cancer has a poor prognosis. We have reported that intraperitoneal radioimmunotherapy using a (64)Cu-labeled antibody ((64)Cu-ipRIT) is a promising adjuvant therapy option to prevent this complication. To achieve personalized (64)Cu-ipRIT, we developed a new in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hihara, Fukiko, Matsumoto, Hiroki, Yoshimoto, Mitsuyoshi, Masuko, Takashi, Endo, Yuichi, Igarashi, Chika, Tachibana, Tomoko, Shinada, Mitsuhiro, Zhang, Ming-Rong, Kurosawa, Gene, Sugyo, Aya, Tsuji, Atsushi B., Higashi, Tatsuya, Kurihara, Hiroaki, Ueno, Makoto, Yoshii, Yukie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146758/
https://www.ncbi.nlm.nih.gov/pubmed/35628616
http://dx.doi.org/10.3390/ijms23105807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146758/
https://www.ncbi.nlm.nih.gov/pubmed/35628616
http://dx.doi.org/10.3390/ijms23105807

Ejemplares similares